IP Library › Granted Patent US 12,351,633
Granted Patent B2
US 12,351,633 · App. 17/938,109 · Granted Jul 8, 2025

PD-1 and PD-L1 binding agents

Inventors: Nikolai Kley (Newton, MA); Jan Tavernier (Balegem, BE); Lennart Zabeau (Zwijnaarde, BE); Erik Depla (Zwijnaarde, BE)
Assignees: Orionis Biosciences, Inc.; Orionis Biosciences BV
C07K16/2827A61P35/00C07K14/56C07K14/565A61K2039/505C07K2317/21C07K2317/565C07K2317/569C07K2317/76C07K2319/02C07K2319/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,351,633
App. No.
17/938,109
Granted
Jul 8, 2025
Kind
B2
Abstract

The present invention relates, in part, to agents that bind PD-1 or PD-L1 and their use as diagnostic and therapeutic agents. The present invention further relates to pharmaceutical compositions comprising the PD-1 or PD-L1 binding agents and their use in the treatment of various diseases.

Claims (26)

1. A PD-1 binding agent comprising at least one targeting moiety comprising three complementarity determining regions (CDR1, CDR2, and CDR3), wherein:

(a) CDR1 comprises the amino acid sequence of SEQ ID NO: 2, (b) CDR2 comprises the amino acid sequence of SEQ ID NO: 24; and (c) CDR3 comprises the amino acid sequence of SEQ ID NO: 55;

(a) CDR1 comprises the amino acid sequence of SEQ ID NO: 3, (b) CDR2 comprises the amino acid sequence of SEQ ID NO: 24; and (c) CDR3 comprises the amino acid sequence of SEQ ID NO: 56;

(a) CDR1 comprises the amino acid sequence of SEQ ID NO: 4, (b) CDR2 comprises the amino acid sequence of SEQ ID NO: 25; and (c) CDR3 comprises the amino acid sequence of SEQ ID NO: 57;

(a) CDR1 comprises the amino acid sequence of SEQ ID NO: 5, (b) CDR2 comprises the amino acid sequence of SEQ ID NO: 26; and (c) CDR3 comprises the amino acid sequence of SEQ ID NO: 58;

(a) CDR1 comprises the amino acid sequence of SEQ ID NO: 6, (b) CDR2 comprises the amino acid sequence of SEQ ID NO: 27; and (c) CDR3 comprises the amino acid sequence of SEQ ID NO: 59;

(a) CDR1 comprises the amino acid sequence of SEQ ID NO: 7, (b) CDR2 comprises the amino acid sequence of SEQ ID NO: 27; and (c) CDR3 comprises the amino acid sequence of SEQ ID NO: 59;

(a) CDR1 comprises the amino acid sequence of SEQ ID NO: 8, (b) CDR2 comprises the amino acid sequence of SEQ ID NO: 28; and (c) CDR3 comprises the amino acid sequence of SEQ ID NO: 60;

(a) CDR1 comprises the amino acid sequence of SEQ ID NO: 9, (b) CDR2 comprises the amino acid sequence of SEQ ID NO: 29; and (c) CDR3 comprises the amino acid sequence of SEQ ID NO: 61; or

(a) CDR1 comprises the amino acid sequence of SEQ ID NO: 10, (b) CDR2 comprises the amino acid sequence of SEQ ID NO: 30; and (c) CDR3 comprises the amino acid sequence of SEQ ID NO: 62.

2. The PD-1 binding agent of claim 1 , wherein

(a) CDR1 comprises the amino acid sequence of SEQ ID NO: 2, (b) CDR2 comprises the amino acid sequence of SEQ ID NO: 24; and (c) CDR3 comprises the amino acid sequence of SEQ ID NO: 55.

3. The PD-1 binding agent of claim 1 , wherein the targeting moiety is a single-domain antibody.

4. The PD-1 binding agent of claim 3 , wherein the targeting moiety comprises a VHH or a humanized VHH.

5. The PD-1 binding agent of claim 1 , wherein the targeting moiety comprises an amino acid sequence having at least 90% identity with one of SEQ ID NOs: 70-83 without the AAA linker, HA tag, and terminal histidine tag sequence.

6. The PD-1 binding agent of claim 1 , wherein the targeting moiety comprises one or more additional targeting moieties.

7. A recombinant nucleic acid composition encoding the PD-1 binding agent of claim 1 .

8. A host cell comprising the nucleic acid of claim 7 .

9. The PD-1 binding agent of claim 1 , wherein (a) CDR1 comprises the amino acid sequence of SEQ ID NO: 3, (b) CDR2 comprises the amino acid sequence of SEQ ID NO: 24; and (c) CDR3 comprises the amino acid sequence of SEQ ID NO: 56.

10. The PD-1 binding agent of claim 1 , wherein (a) CDR1 comprises the amino acid sequence of SEQ ID NO: 4, (b) CDR2 comprises the amino acid sequence of SEQ ID NO: 25; and (c) CDR3 comprises the amino acid sequence of SEQ ID NO: 57.

11. The PD-1 binding agent of claim 1 , wherein (a) CDR1 comprises the amino acid sequence of SEQ ID NO: 5, (b) CDR2 comprises the amino acid sequence of SEQ ID NO: 26; and (c) CDR3 comprises the amino acid sequence of SEQ ID NO: 58.

12. The PD-1 binding agent of claim 1 , wherein (a) CDR1 comprises the amino acid sequence of SEQ ID NO: 6, (b) CDR2 comprises the amino acid sequence of SEQ ID NO: 27; and (c) CDR3 comprises the amino acid sequence of SEQ ID NO: 59.

13. The PD-1 binding agent of claim 1 , wherein (a) CDR1 comprises the amino acid sequence of SEQ ID NO: 7, (b) CDR2 comprises the amino acid sequence of SEQ ID NO: 27; and (c) CDR3 comprises the amino acid sequence of SEQ ID NO: 59.

14. The PD-1 binding agent of claim 1 , wherein (a) CDR1 comprises the amino acid sequence of SEQ ID NO: 8, (b) CDR2 comprises the amino acid sequence of SEQ ID NO: 28; and (c) CDR3 comprises the amino acid sequence of SEQ ID NO: 60.

15. The PD-1 binding agent of claim 1 , wherein (a) CDR1 comprises the amino acid sequence of SEQ ID NO: 9, (b) CDR2 comprises the amino acid sequence of SEQ ID NO: 29; and (c) CDR3 comprises the amino acid sequence of SEQ ID NO: 61.

16. The PD-1 binding agent of claim 1 , wherein (a) CDR1 comprises the amino acid sequence of SEQ ID NO: 10, (b) CDR2 comprises the amino acid sequence of SEQ ID NO: 30; and (c) CDR3 comprises the amino acid sequence of SEQ ID NO: 62.

Assignments (4)
CHANGE OF NAME Recorded Jun 2, 2025
From: ORIONIS BIOSCIENCES NV
To: ORIONIS BIOSCIENCES BV
Reel/Frame 071493/0091 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 13, 2023
From: KLEY, NIKOLAI
To: ORIONIS BIOSCIENCES, INC.
Reel/Frame 062366/0878 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 13, 2023
From: TAVERNIER, JAN; ZABEAU, LENNART; DEPLA, ERIK
To: ORIONIS BIOSCIENCES NV
Reel/Frame 062366/0881 →
CHANGE OF NAME Recorded Jan 13, 2023
From: ORIONIS BIOSCIENCES NV
To: ORIONIS BIOSCIENCES BV
Reel/Frame 062381/0801 →
Continuity (3)
Continuation 16636501
Provisional Application 62542921 · Aug 9, 2017
Related Publication 20230295304A1 · Sep 21, 2023
References Cited (112)
US 5914254A · Mascarenhas et al. · 1999 [cited by applicant]
US 8980267B2 · Grewal et al. · 2015 [cited by applicant]
US 9139634B2 · Morrison et al. · 2015 [cited by applicant]
US 9492562B2 · Tavernier et al. · 2016 [cited by applicant]
US 9534056B2 · Grewal et al. · 2017 [cited by applicant]
US 9732135B2 · Tavernier et al. · 2017 [cited by applicant]
US 9878014B2 · Tavernier et al. · 2018 [cited by applicant]
US 9914759B2 · Tavernier et al. · 2018 [cited by applicant]
US 9932409B2 · Tavernier et al. · 2018 [cited by applicant]
US 10034919B2 · Tavernier et al. · 2018 [cited by applicant]
US 10035835B2 · Tavernier et al. · 2018 [cited by applicant]
US 10072059B2 · Tavernier et al. · 2018 [cited by applicant]
US 10407480B2 · Tavernier et al. · 2019 [cited by applicant]
US 10640542B2 · Tavernier et al. · 2020 [cited by applicant]
US 20100172868A1 · Morrison et al. · 2010 [cited by applicant]
US 20100297076A1 · Morrison et al. · 2010 [cited by applicant]
US 20110020273A1 · Chang et al. · 2011 [cited by applicant]
US 20110081341A1 · Honjo et al. · 2011 [cited by applicant]
US 20110104112A1 · Morrison et al. · 2011 [cited by applicant]
US 20110224407A1 · Langer et al. · 2011 [cited by applicant]
US 20110274658A1 · Silver et al. · 2011 [cited by applicant]
US 20130183298A1 · Le et al. · 2013 [cited by applicant]
US 20130230517A1 · Grewal et al. · 2013 [cited by applicant]
US 20140271462A1 · Ho et al. · 2014 [cited by applicant]
US 20140348789A1 · Tavernier et al. · 2014 [cited by applicant]
US 20150139951A1 · Grewal et al. · 2015 [cited by applicant]
US 20150313965A1 · Pogue et al. · 2015 [cited by applicant]
US 20180186894A1 · Tavernier et al. · 2018 [cited by applicant]
US 20180333465A1 · Tavernier et al. · 2018 [cited by applicant]
US 20180334488A1 · Tavernier et al. · 2018 [cited by applicant]
US 20180334489A1 · Tavernier et al. · 2018 [cited by applicant]
US 20190010199A1 · Tavernier et al. · 2019 [cited by applicant]
US 20190071500A1 · Kley et al. · 2019 [cited by applicant]
US 20190144553A1 · Kley et al. · 2019 [cited by applicant]
US 20190194284A1 · Kley et al. · 2019 [cited by applicant]
US 20190202934A1 · Tavernier et al. · 2019 [cited by applicant]
US 20190351021A1 · Tavernier et al. · 2019 [cited by applicant]
US 20190352406A1 · Tavernier et al. · 2019 [cited by applicant]
US 20190367575A1 · Tavernier et al. · 2019 [cited by applicant]
US 20190367604A1 · Kley et al. · 2019 [cited by applicant]
US 20200071414A1 · Kley et al. · 2020 [cited by applicant]
US 20200087411A1 · Kley et al. · 2020 [cited by applicant]
RU 2011127226A · 2013 [cited by applicant]
WO WO9102754A1 · 1991 [cited by applicant]
WO WO03033720A2 · 2003 [cited by applicant]
WO WO2006053883A1 · 2003 [cited by applicant]
WO WO2006115800A2 · 2006 [cited by applicant]
WO WO2008014612A1 · 2008 [cited by applicant]
WO WO2008124086A2 · 2008 [cited by applicant]
WO WO2009003145A1 · 2008 [cited by applicant]
WO WO2009013484A1 · 2009 [cited by applicant]
WO WO2009039409A1 · 2009 [cited by applicant]
WO WO2010036918A2 · 2010 [cited by applicant]
WO WO2010066740A1 · 2010 [cited by applicant]
WO WO2011020783A2 · 2011 [cited by applicant]
WO WO2011029870A1 · 2011 [cited by applicant]
WO WO2012170072A1 · 2012 [cited by applicant]
WO WO2013053008A2 · 2013 [cited by applicant]
WO WO2013059885A2 · 2013 [cited by applicant]
WO WO2013107791A1 · 2013 [cited by applicant]
WO WO2013134138A1 · 2013 [cited by applicant]
WO WO2015007520A1 · 2015 [cited by applicant]
WO WO2015007536A2 · 2015 [cited by applicant]
WO WO2015007542A1 · 2015 [cited by applicant]
WO WO2015007903A1 · 2015 [cited by applicant]
WO WO2015018528A1 · 2015 [cited by applicant]
WO WO2017077382A1 · 2017 [cited by applicant]
WO WO2017134302A2 · 2017 [cited by applicant]
WO WO2017194782A2 · 2017 [cited by applicant]
Acres, et al., “Fusokine Interleukin-2/Interleukin-18, a Novel Potent Innate and Adaptive Immune Stimulator with Decreased Toxicity,” Cancer Res., vol. 65, No. 20, pp. 9536-9546, 2005. [cited by applicant]
Baba, et al., “Identification of CCR6, the Specific Receptor for a Novel Lymphocyte-Directed CC Chemokine LARC,” The Journal of Biological Chemistry, vol. 272, No. 23, pp. 14893-14898, 1997. [cited by applicant]
Barbara, et al., “Dissociation of TNF-α cytotoxic and proinflammatory activities by p55 receptor-and p75 receptor-selective TNF-α mutants,” EMBO Journal, vol. 13, No. 4, pp. 843-850, 1994. [cited by applicant]
Bork, et al., “Go hunting in sequence databases but watch out for the traps.” Trends in Genetics, vol. 12, pp. 125-427, 1996. [cited by applicant]
Bork, “Powers and Pitfalls in Sequence Analysis: The 70% Hurdle,” Genome Research, vol. 10, pp. 398-400, 2000. [cited by applicant]
Boschert, et al., “Single chain TNF derivatives with individually mutated receptor binding sites reveal differential stoichiometry of ligand receptor complex formation for TNFR1 and TNFR2,” Cellular Signalling 22 (7):10… [cited by applicant]
Bremer, et al., “Superior activity of fusion protein scFvRit:sFasL over cotreatment with rituximab and Fas agonists,” Cancer Res. 68: 597-604, 2008. [cited by applicant]
Camacho, et al., “Structure of an Interleukin-1β Mutant With Reduced Bioactivity Shows Multiple Subtle Changes in Conformation That Affect Protein-Protein Recognition,” Biochemistry, vol. 32, No. 34, pp. 8749-8757, 1993. [cited by applicant]
Coulstock, et al., “Liver-Targeting of Interferon-Alpha with Tissue Specific Domain Antibodies,” PLOS ONE, vol. 8, No. 2, pp. 1-11, 2013. [cited by applicant]
De Bruyn, et al., “Antibody-Based Fusion Proteins to Target Death Receptors in Cancer,” Cancer Letters, vol. 332, pp. 175-183, 2013. [cited by applicant]
Deffar, et al., “Nanobodies—The New Concept in Antibody Engineering,” African Journal of Biotechnology, vol. 8, No. 12, pp. 2645-2652, 2009. [cited by applicant]
Dijkmans, et al., “Murine Interferon-γ Interleukin-1 Fusion Proteins Used as Antigens for the Generation of Hybridomas Producing Monoclonal Anti-Interleukin-1 Antibodies,” Cytokine, vol. 3, No. 2, pp. 134-140, 1991. [cited by applicant]
Dimitrov, “Engineered CH2 Domains (Nanoantibodies),” mAbs, Landes Bioscience, vol. 1, No. 1, pp. 26-28, 2009. [cited by applicant]
Frey, et al., “Antibody-Based Targeting of Interferon-Alpha to the Tumor Neovasculature: A Critical Evaluation,” ntegrative Biology, vol. 3, pp. 468-478, 2011. [cited by applicant]
Garcin, et al., “High Efficiency cell-specific targeting of cytokine activity,” Nature Communications, vol. 5, No. 8, 9 pages, 2014. [cited by applicant]
Garlanda, et al., “The Interleukin-1 Family: Back to the Future,” Immunity, 39 (6): pp. 1003-1018, Dec. 12, 2013. [cited by applicant]
Holler, et al., “Two Adjacent Trimeric Fas Ligands are Required for Fas Signaling and Formation of a Death-Inducing Signaling Complex,” Molecular and Cellular Biology, vol. 23, No. 4, pp. 1428-1440, 2003. [cited by applicant]
Huang, et al., “A Trimeric Anti-HER2/neu ScFv and Tumor Necrosis Factor-[alpha] Fusion Protein Induces HER2/Neu Signaling and Facilitates Repair of Injured Epithelia,” The Journal of Pharmacology and Experimental Therap… [cited by applicant]
Idoyaga, et al., “Comparable T helper 1 (Th1) and CD8 T-cell immunity by targeting HIV gag p24 to CD8 dendritic cells within antibodies to Langerin, DEC205, and Clec9A,” PNAS, vol. 108, No. 6, pp. 2384-2389, Jan. 24, 20… [cited by applicant]
International Search Report & Written Opinion, PCT Application No. PCT/EP2017/052544, dated Jun. 6, 2017, 16 pages. [cited by applicant]
Kircheis, et al., “Biological activity of mutants of human tumour necrosis factor-alpha,” Immunology, pp. 433-438, Jul. 1, 1992. [cited by applicant]
Krippner-Heidenreich, et al., “Single-Chain TNF, a TNF Derivative with Enhanced Stability and Antitumoral Activity,” The Journal of Immunology, vol. 180, pp. 8176-8183, 2008. [cited by applicant]
Lahoud, et al., “Targeting Antigen to Mouse Dendritic Cells via Clec9A Induces Potent CD4 T Cell Responses Biased toward a Follicular Helper Phenotype,” The Journal Of Immunology, vol. 187, No. 2, Jul. 15, 2011, pp. 842… [cited by applicant]
Loetscher, et al., “Human Tumor Necrosis Factor a (TNFα) Mutants with Exclusive Specificity for 55-kDA or 75-kDa TNF Receptors,” Journal of Biological Chemistry, American Society For Biochemistry and Molecular Biology, … [cited by applicant]
Masci, et al., “New and Modified Interferon alfas: Preclinical and Clinical Data,” Current Oncology Reports, vol. 5, pp. 108-113, 2003. [cited by applicant]
Minn, “Interferons and the Immunogenic Effects of Cancer Therapy,” Trends In Immunology, vol. 36, No. 11, pp. 725-737, Nov. 1, 2015. [cited by applicant]
Ngo, et al., “Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox. The Protein Folding Problem and Tertiary Structure Prediction,” Edited by: Mertz et al., (Birkhauser, Boston), pp. 491-495… [cited by applicant]
Pan, et al., “Mutation of the IFNAR-1 Receptor Binding Site of Human IFN-α2 Generates Type I IFN Competitive Antagonists,” Biochemistry, vol. 47, pp. 12018-12027, 2008. [cited by applicant]
Patris, et al., “Nanoimmunoassay onto a screen printed electrode for HER2 breast cancer biomarker determination,” Talanta, 2014, vol. 130, pp. 164-170, 2014. [cited by applicant]
Penafuerte, et al., “The Human Ortholog of Granulocyte Macrophage Colony-Stimulating Factor and Interleukin-2 fusion Protein Induces Potent Ex Vivo Natural Killer Cell Activation and Maturation,” Cancer Res, vol. 69, No… [cited by applicant]
Picco, et al., “Targeting DNGR-1 (CLEC9A) with antibody/MUC1 peptide conjugates as a vaccine for carcinomas”, European Journal Of Immunology, vol. 44, No. 7, pp. 1947-1955, Apr. 17, 2014. [cited by applicant]
Puskas, et al., “Development of an attenuated interleukin-2 fusion protein than can be activated by tumour-expressed proteases,” Immunology, vol. 133, No. 2, pp. 206-220, Jun. 23, 2011. [cited by applicant]
Rafei, et al., “A MCP1 Fusokine with CCR2-Specific Tumoricidal Activity,” Molecular Cancer, vol. 10, No. 121, pp. 1-11, 2011. [cited by applicant]
Rafei, et al., “An Engineered GM-CSF-CCL2 Fusokine Is A Potent Inhibitor of CCR2-Driven Inflammation as Demonstrated in a Murine Model of Inflammatory Arthritis,” The Journal of Immunology, vol. 183, pp. 1759-1766, 2009. [cited by applicant]
Roisman, et al., “Structure of the Interferon-Receptor Complex Determined by Distant Constraints from Double Mutant Cycles and Flexible Docking,” PNAS, vol. 98, No. 23, pp. 13231-13236, 2001. [cited by applicant]
Rovero, et al., “Insertion of the DNA for the 163-171 Peptide of IL 1 II Enables a DNA Vaccine Encoding p185 [cited by applicant]
Sancho, et al., “Identification of a dendritic cell receptor that couples sensing of necrosis to immunity”, Nature, Nature Publishing Group, United Kingdom, vol. 458, No. 7240, pp. 899-903, Apr. 16, 2009. [cited by applicant]
Schutyser, et al., “The CC Chemokine CCL20 and its Receptor CCR6,” Cytokine & Growth Factor Reviews, vol. 14, pp. 409-426, 2003. [cited by applicant]
Vaneycken, et al., “Preclinical Screening of Anti-HER2 Nanobodies for Molecular Imaging of Breast Cancer”, The ASEB Journal, vol. 25, pp. 2433-2446, 2011. [cited by applicant]
Weber, et al., “Single Amino Acid Changes that Render Human IFN-α2 Biologically Active on Mouse Cells,” The EMBO Journal, vol. 6, No. 3, pp. 591-598, 1987. [cited by applicant]
Wells, “Additivity of Mutational Effects in Proteins,” Biochemistry, vol. 29, No. 37, pp. 8509-8517, 1990. [cited by applicant]
Wesolowski, et al., “Single Domain Antibodies: Promising Experimental and Therapeutic Tools in Infection and Immunity,” Med. Microbiol. Immunol., vol. 198, pp. 157-174, 2009. [cited by applicant]
Zitvogel, et al., “Type I interferons in anticancer immunity,” The Journal of Immunology, vol. 15, No. 7, pp. 405-141, Jun. 1, 2015. [cited by applicant]